Showing 13 to 13 of 13 results
forbes.com
🌐 85% Global Worthiness
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Progress
40% Bias Score
Good Health and Well-being
Showing 13 to 13 of 13 results